购物车
- 全部删除
- 您的购物车当前为空
Certolizumab pegol (Certolizumab) 是经过重组和聚乙二醇化处理的人源化单克隆抗体抗原结合片段,它选择性地靶向并中和肿瘤坏死因子-α (TNF-α)。适用于类风湿关节炎和克罗恩病的研究领域。
Certolizumab pegol (Certolizumab) 是经过重组和聚乙二醇化处理的人源化单克隆抗体抗原结合片段,它选择性地靶向并中和肿瘤坏死因子-α (TNF-α)。适用于类风湿关节炎和克罗恩病的研究领域。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 | |
50 mg | 询价 | 期货 |
产品描述 | Certolizumab pegol (Certolizumab) is a recombinant, humanized monoclonal antibody fragment that has been modified with polyethylene glycol (PEG), which selectively targets and neutralizes tumor necrosis factor-alpha (TNF-α). This compound is utilized in the research of rheumatoid arthritis and Crohn's disease [1] [2]. |
CAS No. | 428863-50-7 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 years | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.